Impaired Cerebral Hemodynamics and Cognitive Performance in Patients with Atherothrombotic Disease

Salo Haratz1,2, Galit Weinstein3, Noa Molshazki1

  • 1The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.

Insights

Impaired cerebrovascular reactivity (CVR) is linked to lower cognitive scores, especially executive function, in patients with carotid large-vessel disease. This highlights the critical role of cerebral hemodynamics in maintaining cognitive health.

Area of Science:

  • Neurology
  • Cardiovascular Science
  • Cognitive Neuroscience

Background:

  • Patients with atherothrombotic disease often experience cognitive impairment.
  • Cerebrovascular reactivity (CVR) is a key indicator of cerebral microvascular hemodynamic function.
  • Impaired CVR may contribute to cognitive decline in at-risk populations.

Purpose of the Study:

  • To investigate the association between impaired CVR and cognitive performance.
  • To determine if this association differs in patients with and without carotid large-vessel disease.
  • To explore the impact of cerebral microvascular dysfunction on cognitive domains.

Main Methods:

  • A subgroup of 415 non-demented patients with chronic coronary heart disease were assessed.
  • Cognitive function was evaluated using the Neurotrax Computerized Cognitive Battery.
  • Cerebrovascular reactivity (CVR) was measured using the breath-holding index (BHI) via transcranial Doppler.
  • Carotid plaques were identified using ultrasound.

Main Results:

  • Impaired CVR (BHI <0.47) was associated with lower executive function and global cognitive scores, even after adjusting for confounders.
  • A significant interaction was observed between impaired CVR and carotid large-vessel disease for executive function, memory, and global cognitive scores.
  • In patients with carotid large-vessel disease, impaired CVR markedly reduced performance in executive function, memory, attention, and global cognition.

Conclusions:

  • Impaired CVR, a marker of cerebral microvascular dysfunction, is significantly associated with poorer cognitive function.
  • Executive dysfunction is particularly pronounced in non-demented patients with concomitant carotid large-vessel disease and impaired CVR.
  • Cerebral hemodynamics play a crucial role in maintaining cognitive performance, especially in patients with cerebrovascular disease.
Abstract

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
821
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
595
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613